Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the amendment Cipla and Pulmatrix agreed to stop patient enrollment of the Ph2b study of PUR1900 (itraconazole) at 8 subjects and close the study. Cipla will take sole responsibility for development of PUR1900 in the treatment of Allergic Bronchopulmonary Aspergillosis.
Lead Product(s): Itraconazole
Therapeutic Area: Infections and Infectious Diseases Product Name: PUR1900
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Pulmatrix
Deal Size: Undisclosed Upfront Cash: $22.0 million
Deal Type: Agreement January 08, 2024
Details:
Through the acquisition, Cipla strengthen its wellness portfolio by gaining access of Nozohaem (glycine and Calcium), a unique, gel treatment for nosebleeds that stops the bleeding in moments.
Lead Product(s): Glycine,Calcium
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: Nozohaem
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Actor Pharma
Deal Size: $48.6 million Upfront Cash: $48.6 million
Deal Type: Acquisition September 05, 2023
Details:
Under the terms of the agreement, Cipla will manufacture and market Galvus (vildagliptin) and Galvus combination brands, used in the treatment of type 2 diabetes.
Lead Product(s): Vildagliptin
Therapeutic Area: Endocrinology Product Name: Galvus
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Novartis Pharmaceuticals Corporation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 11, 2023
Details:
ETH45 is a first-in-class inhalable form of Ethris’ proprietary mRNA for treatment of pulmonary alveolar proteinosis (PAP). ETH45 activates granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling in the presence of anti-GM-CF antibodies.
Lead Product(s): ETH45
Therapeutic Area: Rare Diseases and Disorders Product Name: ETH45
Highest Development Status: DiscoveryProduct Type: Large molecule
Recipient: Ethris
Deal Size: $16.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration December 29, 2022
Details:
Solifenacin is a muscarinic receptor antagonist and tamsulosin is an alpha-1A and alpha-1B adrenergic receptor antagonist used to treat benign prostatic hyperplasia.
Lead Product(s): Tamsulosin,Solifenacin Succinate
Therapeutic Area: Urology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2022
Details:
Leuprolide Acetate Injection Depot contains 22.5 mg of leuprolide acetate for 3- month administration given as a single dose injection. . It is supplied as lyophilized microspheres in a single dose vial as a kit with a prefilled syringe.
Lead Product(s): Leuprolide Acetate
Therapeutic Area: Oncology Product Name: Leuprolide Acetate-Generic
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 29, 2022
Details:
Lenalidomide is an immunomodulatory prescription drug which is indicated for several hematological malignancies in adults such as; Multiple Myeloma, Myelodysplastic syndromes, Mantle cell lymphoma, Follicular lymphoma, and Marginal Zone lymphoma.
Lead Product(s): Lenalidomide
Therapeutic Area: Oncology Product Name: Lenalidomide-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2022
Details:
The ‘4-in-1’ combination contains an antiretroviral combination of Abacavir, as an alternative first-line regimen for infants and young children with HIV – in the form of granule-filled capsules.
Lead Product(s): Abacavir,Lamivudine,Lopinavir
Therapeutic Area: Infections and Infectious Diseases Product Name: ABC/3TC/LPV/r
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 14, 2022
Details:
Cipmolnu® (Molnupiravir 200mg), first oral antiviral approved by the UK MHRA for the treatment of mild-to-moderate COVID-19 receives EUA by permission by the Drug Controller General of India.
Lead Product(s): Molnupiravir
Therapeutic Area: Infections and Infectious Diseases Product Name: Cipmolnu
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 28, 2021
Details:
Company received final approval for its Lanreotide acetate-Generic Injection, from USFDA for the treatment of patients with Acromegaly and Gastroenteropancreatic Neuroendocrine Tumors.
Lead Product(s): Lanreotide Acetate
Therapeutic Area: Endocrinology Product Name: Lanreotide Acetate-Generic
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 19, 2021